Abstract: Objective To study the therapeutic effect of different doses of batroxobin in the treatment of sudden deafness with full frequency hearing loss. Methods Individuals who consented to receive Batroxobin treatment for sudden full frequency descending deafness were categorized into three groups based on their level of plasma fibrinogen prior to treatment(also known as Fib). Group A(23 cases)consisted of 1 g/L≤Fib<2 g/L; Group B(41 cases)consisted of 2 g/L≤Fib≤4 g/L, and Group C(22 cases)consisted of Fib>4 g/L; or patients not receiving Batroxobin medication, were assigned to group D(34 cases). Groups A, B and C received 5 Bu, 10 Bu and 15 Bu of batroxobin, respectively, for the first time based on traditional medication treatment, and Fib was rechecked 1-2 days later. Drug use was temporarily stopped if Fib was less than 1 g/L; if Fib(rechecked)was between 1 and 2 g/L, 5 Bu of batroxobin was administered; if 2 g/L was between 1 and 4 g/L, 10 Bu of batroxobin was administered; while if Fib(rechecked)was greater than 4 g/L, 15 Bu of batroxobin was administered. The entire course of treatment involved three doses of batroxobin, ranging in dosage from 15 Bu to 45 Bu. Patients in each group's total effective rate was compared with patient rates throughout the entire course of treatment. Results The average hearing threshold of patients in groups A to D improved after treatment, and the average hearing threshold before and after treatment within the group was statistically significant(P<0.05); The total effective rates of groups A to D were 56.52%, 46.34%, 63.64%, and 20.59%, respectively, with statistical significance(P<0.05). There was a statistically significant difference in total effective rates between groups A and D, B and D, C and D(P<0.05), while there was no statistically significant difference in total effective rates between groups A, B and C(P>0.05); There was no statistically significant difference in efficacy classification between the four groups of patients(P>0.05). Conclusion All four treatment methods are effective, with Group A, Group B, and Group C having better efficacy than Group D. It is believed that in the treatment of sudden deafness with full frequency decline, the addition of batroxobin has better efficacy. However, the difference in initial and maintenance doses of Batroxobin does not affect final efficacy.

Key words: Sudden sensorineural hearing loss with full frequency decline, Batroxobin, Fibrinogen, Case-control study